The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial

Developments in the management of autosomal dominant polycystic kidney disease

(2016) Robert Schrier   Therapeutics and Clinical Risk Management

Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial

(2013) Isao Sakaida et al.   HEPATOLOGY RESEARCH

Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies

(2012) Toshio Mochizuki et al.   Clinical and Experimental Nephrology

Evaluation of urine biomarkers of kidney injury in polycystic kidney disease

(2012) Chirag R. Parikh et al.   KIDNEY INTERNATIONAL

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Summary of Recommendation Statements

(2012)   Kidney International Supplements

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

(2011) Vicente E. Torres et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)

(2011) Masunori Matsuzaki et al.   CARDIOVASCULAR DRUGS AND THERAPY

Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease

(2010) Andreas L. Serra et al.   NEW ENGLAND JOURNAL OF MEDICINE

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Autosomal dominant polycystic kidney disease: the last 3 years

(2009) Vicente E. Torres et al.   KIDNEY INTERNATIONAL